Skip to main content

Advertisement

SpringerLink
Log in

Clinicopathological and Molecular Study of Peritoneal Carcinomatosis Associated with Non-Small Cell Lung Carcinoma

  • Short Communication
  • Published:
Pathology & Oncology Research

Abstract

To retrospectively characterize the molecular features of Non-Small Cell Lung Carcinomas (NSCLC) with peritoneal carcinomatosis (PC), clinicopathological data of 12 patients diagnosed with NSCLC and PC between 2007 and 2016 were collected. Immunohistochemistry and Next Generation Sequencing (NGS) were performed on cases with available material. PC was the initial presentation of NSCLC in 17% of the cases. Overall, patients with PC displayed a poor median survival of 12 weeks. Histology was adenocarcinoma in 11 cases. 37.5% of cases showed PD-L1 immunostaining positivity (50% cut-off). ALK and ROS1 immunostainings were negative. Using NGS, we identified 17 molecular alterations in 9 genes (TP53, KRAS, STK11, BRAF, EGFR, DDR2, ERBB4, SMAD4, CTNNB1) in 88.9% of adenocarcinomas. To the best of our knowledge, 5 of these variants are not referenced in the literature. In conclusion, PC might be the initial presentation of NSCLC. Molecular profiling of our cases did not find any effective targetable alteration, except from high PD-L1 expression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386

    Article  CAS  Google Scholar 

  2. Satoh H, Ishikawa H, Yamashita YT, Kurishima K, Ohtsuka M, Sekizawa K (2001) Peritoneal carcinomatosis in lung cancer patients. Oncol Rep 8(6):1305–1307

    CAS  PubMed  Google Scholar 

  3. Patil T, Aisner DL, Noonan SA, Bunn PA, Purcell WT, Carr LL, Camidge DR, Doebele RC (2016) Malignant pleural disease is highly associated with subsequent peritoneal metastasis in patients with stage IV non-small cell lung cancer independent of oncogene status. Lung Cancer 96:27–32

    Article  Google Scholar 

  4. Sereno M, Rodríguez-Esteban I, Gómez-Raposo C, Merino M, López-Gómez M, Zambrana F et al (2013) Lung cancer and peritoneal carcinomatosis. Oncol Lett 6(3):705–708

    Article  Google Scholar 

  5. Su H-T, Tsai C-M, Perng R-P (2008) Peritoneal carcinomatosis in lung cancer. Respirol 13(3):465–467

    Article  Google Scholar 

  6. McNeill PM, Wagman LD, Neifeld JP (1987) Small bowel metastases from primary carcinoma of the lung. Cancer 59(8):1486–1489

    Article  CAS  Google Scholar 

  7. Okami J, Taniguchi K, Higashiyama M, Maeda J, Oda K, Orita N, Koizumi K, Kodama K, Kato K (2007) Prognostic factors for gefitinib-treated postoperative recurrence in non-small cell lung cancer. Oncology 72(3–4):234–242

    Article  CAS  Google Scholar 

  8. Klughammer B, Brugger W, Cappuzzo F, Ciuleanu T, Mok T, Reck M, Tan EH, Delmar P, Klingelschmitt G, Yin AY, Spleiss O, Wu L, Shames DS (2016) Examining treatment outcomes with Erlotinib in patients with advanced non-small cell lung cancer whose tumors harbor uncommon EGFR mutations. J Thorac Oncol 11(4):545–555

    Article  Google Scholar 

  9. Shajani-Yi Z, de Abreu FB, Peterson JD, Tsongalis GJ (2018) Frequency of somatic TP53 mutations in combination with known pathogenic mutations in colon adenocarcinoma, non-small cell lung carcinoma, and gliomas as identified by next-generation sequencing. Neoplasia 20(3):256–262

    Article  CAS  Google Scholar 

  10. Marte B (2013) Tumour heterogeneity. Nature 501:327

    Article  CAS  Google Scholar 

  11. Bhattacharya S, Socinski MA, Burns TF (2015) KRAS mutant lung cancer: progress thus far on an elusive therapeutic target. Clin Transl Med 4(1):35

    Article  Google Scholar 

  12. Del Re M, Rofi E, Restante G, Crucitta S, Arrigoni E, Fogli S et al (2017) Implications of KRAS mutations in acquired resistance to treatment in NSCLC. Oncotarget 9(5):6630–6643

    PubMed  PubMed Central  Google Scholar 

  13. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K et al (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455(7216):1069–1075

    Article  CAS  Google Scholar 

  14. Pécuchet N, Laurent-Puig P, Mansuet-Lupo A, Legras A, Alifano M, Pallier K et al (2017) Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer. Oncotarget 8(14):23831–23840

    Article  Google Scholar 

  15. Shinozaki E, Yoshino T, Yamazaki K, Muro K, Yamaguchi K, Nishina T et al (2017) Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study. Br J Cancer 117(10):1450–1458

    Article  CAS  Google Scholar 

  16. Carter J, Tseng L-H, Zheng G, Dudley J, Illei P, Gocke CD, Eshleman JR, Lin MT (2015) Non-p.V600E BRAF mutations are common using a more sensitive and broad detection tool. Am J Clin Pathol 144(4):620–628

    Article  CAS  Google Scholar 

  17. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, Hussain J, Reis-Filho JS, Springer CJ, Pritchard C, Marais R (2010) Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140(2):209–221

    Article  CAS  Google Scholar 

  18. Cancer Genome Atlas Research Network (2014) Comprehensive molecular profiling of lung adenocarcinoma. Nature 511(7511):543–550

    Article  Google Scholar 

Download references

Funding

Institutional funding.

Author information

Author notes

  1. Hussein Nassereddine and Aurélie Sannier contributed equally to this work.

Authors and Affiliations

  1. Assistance Publique – Hôpitaux de Paris, département de pathologie, Hôpital Bichat-Claude Bernard, Paris, France

    Hussein Nassereddine, Aurélie Sannier, Claire Danel, Anne Couvelard & Aurélie Cazes

  2. Department of pathology, AP-HP, Bichat- Hospital, 46 rue Henri Huchard 75877, 18, Paris Cedex, France

    Hussein Nassereddine

  3. Université de Paris, Paris, France

    Aurélie Sannier, Solenn Brosseau, Antoine Khalil, Simon Msika, Claire Danel, Anne Couvelard & Aurélie Cazes

  4. APHP, service d’Oncologie Thoracique, Hôpital Bichat-Claude Bernard, Paris, France

    Solenn Brosseau

  5. APHP, service d’Oncologie, Hôpital Bichat-Claude Bernard, Paris, France

    Jean-Michel Rodier

  6. APHP, service de Radiologie, Hôpital Bichat-Claude Bernard, Paris, France

    Antoine Khalil

  7. APHP, service de Chirurgie Générale et Digestive, Hôpital Bichat-Claude Bernard, Paris, France

    Simon Msika

  8. APHP, laboratoire de Génétique, Hôpital Bichat-Claude Bernard, Paris, France

    Nathalie Théou-Anton

Authors
  1. Hussein Nassereddine
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aurélie Sannier
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Solenn Brosseau
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jean-Michel Rodier
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Antoine Khalil
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Simon Msika
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Claire Danel
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Anne Couvelard
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Nathalie Théou-Anton
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Aurélie Cazes
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Nassereddine, Sannier, Danel, Couvelard, Cazes. Acquisition, analysis, and interpretation of data: Nassereddine, Sannier, Théou-Anton, Brosseau, Rodier, Msika, Khalil, Couvelard, Cazes. Drafting of the manuscript: Nassereddine, Sannier, Couvelard, Cazes. Drafting the article or revising it critically for important intellectual content: Brosseau, Rodier, Khalil, Msika, Danel, and Théou-Anton. Final approval of the version to be published: All authors approved this version to be published. Guarantor for the article: Cazes.

Corresponding author

Correspondence to Hussein Nassereddine.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

This research didn’t involve any procedure/trial on living human individual.

This study was approved by our Institutional Review Board (IRB00006477-N°2018–044).

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nassereddine, H., Sannier, A., Brosseau, S. et al. Clinicopathological and Molecular Study of Peritoneal Carcinomatosis Associated with Non-Small Cell Lung Carcinoma. Pathol. Oncol. Res. 26, 2795–2800 (2020). https://doi.org/10.1007/s12253-019-00713-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-019-00713-1

Keywords

Search

Navigation